ImpediMed Limited
ImpediMed Limited
Your view on IPDQF
Overview
What the company does, where it operates, and who runs it.
About ImpediMed Limited
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Parmjot Bains
- Headquarters
- 50 Parker Court, Pinkenba, QLD, AU
- Industry
- Medical - Devices
- Sector
- Healthcare
- CEO
- Parmjot Bains
- Headquarters
- 50 Parker Court, Pinkenba, QLD, AU
ImpediMed Limited, a medical software technology company, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally.
The company offers SOZO, a noninvasive BIS device for the assessment of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications.
It sells its devices to hospitals and clinics. The company was incorporated in 1999 and is headquartered in Pinkenba, Australia.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for ImpediMed Limited, and the rating behind it. IPDQF last traded at $0.01; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for ImpediMed Limited. Starting points for ImpediMed Limited: EPS -$0.01, beta 1.42 — an Medical - Devices name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for ImpediMed Limited. ImpediMed Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for ImpediMed Limited. Trailing twelve-month EPS for ImpediMed Limited stands at -$0.01. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for ImpediMed Limited. ImpediMed Limited has reported as a listed company since 2012. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
ImpediMed Limited valued side by side against its closest peers. ImpediMed Limited is measured against Medical - Devices peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold ImpediMed Limited, and how their positions are changing. At a $28.5M market value, institutional positions materially move ImpediMed Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by ImpediMed Limited executives and directors. Shares of ImpediMed Limited have traded between $0.0099 and $0.05 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming ImpediMed Limited. ImpediMed Limited is a $28.5M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming ImpediMed Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for ImpediMed Limited. Coverage tracks ImpediMed Limited within Medical - Devices (Healthcare). Press releases and market coverage, newest first.